Inflammatory Disorders of the Esophagus

Surgical Pathology of the GI Tract, Liver, Biliary Tract and Pancreas

Volumn , Issue , 2009, Pages 231-267

  Bennett, Ana E ^a   Goldblum, John R ^a,b   Odze, Robert D ^c,d  

^a LERNER RESEARCH INSTITUTE   (United States)

^b CLEVELAND CLINIC LERNER COLLEGE OF MEDICINE   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84855260452     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-141604059-0.50014-X     Document Type: Chapter

References (273)

1. Pettit M Gastroesophageal reflux disease: Clinical features. Pharm World Sci 2005, 27:417-420.
2. Frierson HF Histology in the diagnosis of reflux esophagitis. Gastroenterol Clin North Am 1990, 19:631-644.
3. Vaezi MF, Richter JR Role of acid and duodenogastroesophageal reflux in gastroesophageal reflux disease. Gastroenterology 1996, 111:1192-1199.
4. Richter J Do we know the cause of reflux disease?. Eur J Gastroenterol Hepatol 1999, 11(Suppl 1):S3-9.
5. Pope CE Acid-reflux disorders. N Engl J Med 1994, 331:656-660.
6. Mittal RK, Balaban DH The esophagogastric junction. N Engl J Med 1997, 336:924-932.
7. Nilsson M, Johnsen R, Ye W, et al: Obesity and estrogen as risk factors for gastroesophageal reflux symptoms JAMA 2003, 290(1):66-72.
8. Wilson LJ, Ma W, Hirschowitz BI Association of obesity with hiatal hernia and esophagitis. Am J Gastroenterol 1999, 94:2840-2844.
9. O'Connor HJ Helicobacter pylori and gastro-oesophageal reflux disease: Clinical implications and management. Aliment Pharmacol Ther 1999, 13:117-127.
10. Knuff TE, Benjamin SB, Worsham GF, et al. Histologic evaluation of chronic gastroesophageal reflux: An evaluation of biopsy methods and diagnostic criteria. Dig Dis Sci 1984, 29:194-201.
11. Levine DS, Blount PL, Rudolph RE, et al. Safety of a systematic endoscopic biopsy protocol in patients with Barrett's esophagus. Am J Gastroenterol 2000, 95:1152-1157.
12. Weinstein WM, Bogoch ER, Bowes KL The normal human esophageal mucosa: A histological reappraisal. Gastroenterology 1975, 68:40-44.
13. Schindlbeck NE, Wiebecke B, Klauser AG, et al. Diagnostic value of histology in non-erosive gastro-esophageal reflux disease. Gut 1996, 39:151-154.
14. Orenstein SR Gastroesophageal reflux. Curr Probl Pediatr 1991, 21:193-241.
15. Ismail-Beigi F, Horton PF, Pope CE Histological consequences of gastroesophageal reflux in man. Gastroenterology 1970, 58:163-174.
16. Johnson LF, DeMeester TR, Haggitt RC Esophageal epithelial response to gastroesophageal reflux: A quantitative study. Am J Dig Dis 1978, 23:498-509.
17. Black DD, Haggitt RC, Orenstein SR, et al. Esophagitis in infants: Morphometric histological diagnosis and correlation with measures of gastroesophageal reflux. Gastroenterology 1990, 98:1408-1414.
18. Haggitt RC Histopathology of reflux-induced esophageal and supraesophageal injuries. Am J Med 2000, 6(Suppl 4a):108-111S. 109.
19. Brown LF, Goldman H, Antonioli DA Intraepithelial eosinophils in endoscopic biopsies of adults with reflux esophagitis. Am J Surg Pathol 1984, 8:899-905.
20. Tummala V, Barwick KW, Sontag SJ, et al. The significance of intraepithelial eosinophils in the histologic diagnosis of gastroesophageal reflux. Am J Clin Pathol 1987, 87:43-48.
21. Gold BD Is gastroesophageal reflux disease really a life-long disease: Do babies who regurgitate grow up to be adults with GERD complications?. Am J Gastroenterol 2006, 101:641-644.
22. Winter HS, Madara JL, Stafford RJ, et al. Intraepithelial eosinophils: A new diagnostic criterion for reflux esophagitis. Gastroenterology 1982, 83:818-823.
23. Orenstein SR Gastroesophageal reflux. Curr Probl Pediatr 1991, 21:193-241.
24. Lee RG Marked eosinophilia in esophageal biopsies. Am J Surg Pathol 1985, 9:475-479.
25. Johnson LF, DeMeester TR, Haggitt RC Esophageal epithelial response to gastroesophageal reflux: A quantitative study. Am J Dig Dis 1978, 23:498-509.
26. Antonioli DA, Furuta GT Allergic eosinophilic esophagitis: A primer for pathologists. Semin Diagn Pathol 2005, 22:266-272.
27. Furuta GT, Straumann A Review article: The pathogenesis and management of eosinophilic oesophagitis. Aliment Pharmacol Ther 2006, 24:173-182.
28. Gonsalves N Food allergies and eosinophilic gastrointestinal illness. Gastroenterol Clin North Am 2007, 36:75-91.
29. Mangano MM, Antonioli DA, Schnitt SJ, et al. Nature and significance of cells with irregular nuclear contours in esophageal mucosal biopsies. Mod Pathol 1992, 5:191-196.
30. Wang HH, Mangano MM, Antonioli DA Evaluation of T-lymphocytes in esophageal mucosal biopsies. Mod Pathol 1994, 7:55-58.
31. Goldblum JR, Whyte RI, Orringer MB, Appelman HD Achalasia. A morphologic study of 42 resected specimens. Am J Surg Pathol 1994, 18:327-337.
32. Rubio CA, Sjodahl K, Lagergren J Lymphocytic esophagitis: a histologic subset of chronic esophagitis. Am J Clin Pathol 2006, 125:432-437.
33. Purdy JK, Golembeski CP, Appelman HD, McKenna BJ Lymphocytic esophagitis: What it is and what it is not. Mod Pathol 2007, 20:128A.
34. Geboes K, Desmet V, Vantrappen G, et al. Vascular changes in the esophageal mucosa. An early histologic sign of esophagitis. Gastrointest Endosc 1980, 26:29-32.
35. Collins BJ, Elliott H, Cloan JM, et al. Oesophageal histology in reflux esophagitis. J Clin Pathol 1985, 38:1265-1272.
36. Singh SP, Odze RD Multinucleated epithelial giant cell changes in esophagitis: A clinicopathologic study of 14 cases. Am J Surg Pathol 1998, 22:93-99.
37. Shekitka KM, Helwig EB Deceptive bizarre stromal cells in polyps and ulcers of the gastrointestinal tract. Cancer 1991, 67:2111-2117.
38. O'Morchoe PJ, Lee DC, Kozak CA Esophageal cytology in patients receiving cytotoxic drug therapy. Acta Cytol 1983, 27:630-634.
39. Fass R, Ofman JJ Gastroesophageal reflux disease: Should we adopt a new conceptual framework?. Am J Gastroenterol 2002, 97:1901-1909.
40. Fass R Distinct phenotypic presentations of gastroesophageal reflux disease: A new view of natural history. Dig Dis 2004, 22:100-107.
41. Fullard M, Kang JY, Neild P, et al. Systematic review: Does gastroesophageal reflux disease progress?. Aliment Pharmacol Ther 2006, 24:33-45.
42. Pace F, Pallota S, Vakil N Gastroesophageal reflux disease is a progressive disease. Dig Liv Dis 2007, 39:409-414.
43. Hetzel DJ, Dent J, Reed WD, et al. Healing and relapse of severe peptic esophagitis after treatment with omeprazole. Gastroenterology 1988, 95:903-912.
44. McDougall NI, Johnston BT, Kee F, et al. Natural history of reflux esophagitis: A 10-year follow up of its effect on patient symptomatology and quality of life. Gut 1996, 38:481-486.
45. Hinder RA, Libby JS, Gorecki P, Bammer T Antireflux surgery. Indications, preoperative evaluation and outcome. Gastroenterol Clin North Am 1999, 28:987-1005.
46. Campos GMR, Peters JH, DeMeester T, et al. Multivariate analysis of factors predicting outcome after laparoscopic Nissen fundoplication. J Gastrointest Surg 1999, 3:292-300.
47. Baehr PH, McDonald GB Esophageal infections: Risk factors, presentation, diagnosis, and treatment. Gastroenterology 1994, 106:509-532.
48. Buss DH, Scharyj M Herpes virus infection of the esophagus and other visceral organs in adults: Incidence and clinical significance. Am J Med 1979, 66:457-462.
49. McDonald GB, Sharma P, Hackman RC, et al. Esophageal infections in immunosuppressed patients after marrow transplantation. Gastroenterology 1985, 88:1111-1117.
50. McBane RD, Gross JB Herpes esophagitis: Clinical syndrome, endoscopic appearance, and diagnosis in 23 patients. Gastrointest Endosc 1991, 37:600-603.
51. Teot LA, Geisinger KR Diagnostic esophageal cytology and its histologic basis. The Esophagus 1995, 179-9796. Brown, Boston, Little. ed 2. D.O. Castell (Ed.).
52. Greenson JK, Beschorner WE, Boitnott JK, et al. Prominent mononuclear cell infiltrate is characteristic of herpes esophagitis. Hum Pathol 1991, 22:541-549.
53. U.S.Public Health Service, Infectious Diseases Society of America Guidelines for the treatment of opportunistic infections in adults and adolescents infected with human immunodeficiency virus. MMWR Morb Mortal Wkly Rep 2004, 53(RR-15):1. Accessed January 1, 2006.
54. Bonacini M, Young T, Laine L The causes of esophageal symptoms in human immunodeficiency virus infection. Arch Intern Med 1991, 151:1567-1572.
55. Chetty R, Roskell DE Cytomegalovirus infection in the gastrointestinal tract. J Clin Pathol 1994, 47:968-972.
56. Wilcox CM, Straub RF, Schwartz DA Prospective endoscopic characterization of cytomegalovirus esophagitis in AIDS. Gastrointest Endosc 1994, 40:481-484.
57. Greenson JK Macrophage aggregates in cytomegalovirus esophagitis. Hum Pathol 1997, 28:375-378.
58. Teot LA, Ducatman BS, Geisinger KR Cytologic diagnosis for cytomegaloviral esophagitis: A report of three acquired immunodeficiency syndrome-related cases. Acta Cytol 1993, 37:93-96.
59. Hackman RC, Wolford JL, Cleaves CA, et al. Recognition and rapid diagnosis of upper gastrointestinal cytomegalovirus infection in marrow transplant recipients. Transplantation 1994, 57:231-237.
60. McDonald GB, Sharma P, Hackman RC, et al. Esophageal infections in immunosuppressed patients after marrow transplantation. Gastroenterology 1985, 88(51):1111-1117.
61. Connolly GM, Hawkins D, Harcourt-Webster JN, et al. Oesophageal symptoms, their causes, treatment, and prognosis in patients with the acquired immunodeficiency syndrome. Gut 1989, 30:1033-1039.
62. Kitchen VS, Helbert M, Francis ND, et al. Epstein-Barr virus associated esophageal ulcers in AIDS. Gut 1990, 31:1223-1225.
63. Siegmund B, Moos V, Loddenkemper C, et al. Esophageal giant ulcer in primary human immunodeficiency virus infection is associated with an infiltration of activated T cells. Scand J Gastroenterol 2007, 42(7):890-895.
64. Wilcox CM, Zaki SR, Coffield LM, et al. Evaluation of idiopathic esophageal ulceration for human immunodeficiency virus. Mod Pathol 1995, 8:568-572.
65. Kodsi BE, Wickremeisinghe PC, Kozinn PJ, et al. Candida esophagitis: A prospective study of 27 cases. Gastroenterology 1976, 71:715-719.
66. Walsh TJ, Merz WG Pathologic features in the human alimentary tract associated with invasiveness of Candida tropicalis. Am J Clin Pathol 1986, 85:498-502.
67. Mathieson R, Dutta SK Candida esophagitis. Dig Dis Sci 1983, 28:365-370.
68. Wilcox CM, Karowe MW Esophageal infections: Etiology, diagnosis, and management. Gastroenterol 1994, 2(3):88-206.
69. Rywlin AM, Ortega R Glycogenic acanthosis of the esophagus. Arch Pathol 1970, 90:439-443.
70. Kay PS, Soetikno RM, Mindelzun R, et al. Diffuse esophageal glycogenic acanthosis: An endoscopic marker of Cowden's disease. Am J Gastroenterol 1997, 92:1038-1040.
71. Bender MD, Allison J, Cuartas R, et al. Glycogenic acanthosis of the esophagus: A form of benign epithelial hyperplasia. Gastroenterology 1973, 65:373-380.
72. Bertoni G, Sassatelli R, Nigrisoli E, et al. Ectopic sebaceous glands in the esophagus: Report of three new cases and review of the literature. Am J Gastroenterol 1994, 89:1884-1887.
73. Barbaro G, Barbarini G, Calderon W, et al. Fluconazole versus itraconazole for Candida esophagitis in acquired immunodeficiency syndrome. Candida esophagitis. Gastroenterology 1996, 111:1169-1177.
74. Pappas PG, Rex JH, Sobel JD, et al. Guidelines for the treatment of candidiasis. Clin Infect Dis 2004, 1538(2):161-189.
75. Arathoon EG, Gotuzzo E, Noriega LM, et al. Randomized, double-blind, multicenter study of caspofungin versus amphotericin B for treatment of oropharyngeal and esophageal candidiasis. Antimicrob Agents Chemother 2002, 46:451-457.
76. Wagner C, Graninger W, Tresterl E, Joukhadar C The echicandins: Comparison of their pharmacokinetics and clinical applications. Pharmacology 2006, 78(4):161-177.
77. Walsh TJ, Belitos NJ, Hamilton SR Bacterial esophagitis in immunocompromised patients. Arch Intern Med 1986, 146:1345-1348.
78. Eng J, Sabanthan S Tuberculosis of the esophagus. Dig Dis Sci 1991, 36:536-540.
79. Forsmark CE, Wilcox CM, Darragh TM, et al. Disseminated histoplasmosis in AIDS: An unusual case of esophageal involvement and gastrointestinal bleeding. Gastrointest Endosc 1990, 36:604-605.
80. de Oliveira RB, Troncon LE, Dantas RO, Menghelli UG Gastrointestinal manifestations of Chagas' disease. Am J Gastroenterol 1998, 93(6):884-889.
81. Kikendall JW, Friedman AC, Oyewole MA, et al. Pill-induced esophageal injury. Case reports and review of the medical literature. Dig Dis Sci 1983, 28:174-182.
82. Bott S, Prakash C, McCallum RW Medication-induced esophageal injury: Survey of the literature. Am J Gastroenterol 1987, 82:758-763.
83. Boyce HW Drug-induced esophageal damage: Diseases of medical progress. Gastrointest Endosc 1998, 47:547-550.
84. Abraham SC, Yardley JH, Wu T-T Erosive injury to the upper gastrointestinal tract in patients receiving iron medication: An unrecognized entity. Am J Surg Pathol 1999, 23:1241-1247.
85. Abraham SC, Cruz-Correa M, Lee LA, et al. Alendronate-associated esophageal injury: Pathologic and endoscopic features. Mod Pathol 1999, 12:1152-1157.
86. Semble EL, Wu WC, Castell DO Nonsteroidal anti-inflammatory drugs and esophageal injury. Semin Arthritis Rheum 1989, 19:99-109.
87. Taha AS, Dahill S, Nakshabendi I, et al. Oesophageal histology in long term users of non-steroidal anti-inflammatory drugs. J Clin Pathol 1994, 47:705-708.
88. Isolauri J, Markkula H Lye ingestion and carcinoma of the esophagus. Acta Chir Scand 1989, 155:269-271.
89. de Jong AL, Macdonald R, Ein S, et al. Corrosive esophagitis in children: A 30-year review. Int J Pediatr Otorhinolaryngol 2001, 57:203-211.
90. Garcia Diaz E, Castro Fernandez M, Romero Gomez M, et al. Upper gastrointestinal tract injury caused by ingestion of caustic substances. Gastroenterol Hepatol 2001, 24:191-195.
91. Ein SH, Shandling B, Stephens CA Twenty-one year experience with the pediatric gastric tube. J Pediatr Surg 1987, 22(1):77-81.
92. Friedman EM Caustic ingestions and foreign bodies in the aerodigestive tract of children. Pediatr Clin North Am 1989, 36(6):1403-1410.
93. Appelqvist P, Salmo M Lye corrosion carcinoma of the esophagus: A review of 63 cases. Cancer 1980, 45:2655-2658.
94. Spechler SJ, Genta RM, Souza RF Thoughts on the complex relationship between gastroesophageal reflux disease and eosinophilic esophagitis. Am J Gastroenterol 2007, 102:1301-1306.
95. Liacouras CA, Ruchelli E Eosinophilic esophagitis. Curr Opin Pediatr 2004, 16:560-566.
96. Justinich CJ, Ricci A, Kalafus DA, et al. Activated eosinophils in esophagitis in children: A transmission electron microscopy study. J Pediatr Gastroenterol Nutr 1997, 25:194-198.
97. Markowitz JE, Spergel JM, Ruchelli E, Liacouras CA Elemental diet is an effective treatment for eosinophilic esophagitis in children and adolescents. Am J Gastroenterol 2003, 98:777-782.
98. Mishra A, Rothenberg ME Intratracheal IL-13 induces eosinophilic esophagitis by an IL-5, eotaxin-1, and STAT6-dependent mechanism. Gastroenterology 2003, 125:1419-1427.
99. Mishra A, Hogan S, Lee J, Foster P, et al. Fundamental signals that regulate eosinophil homing to the gastrointestinal tract. J Clin Invest 1999, 103:1719-1727.
100. Blanchard C, Wang N, Stringer KF, et al. Eotaxin-3 and a uniquely conserved gene-expression profile in eosinophilic esophagitis. J Clin Invest 2006, 116:536-547.
101. Genta RM, Spechler SJ, Souza RF The twentieth eosinophil. Adv Anat Pathol 2007, 14:340-343.
102. Kaplan M, Mutlu EA, Jakate S, et al. Endoscopy in eosinophilic esophagitis: "Feline" esophagus and perforation risk. Clin Gastroenterol Hepatol 2003, 1:433-437.
103. Siafakas CG, Ryan CK, Brown MR, Miller TL Multiple esophageal rings: An association with eosinophilic esophagitis: Case report and review of the literature. Am J Gastroenterol 2000, 95:1572-1575.
104. Potter JW, Saeian K, Staff D, et al. Eosinophilic esophagitis in adults: An emerging problem with unique esophageal features. Gastrointest Endosc 2004, 59:355-361.
105. Furuta GT, Liacouras CA, Collins MH, et al. Eosinophilic esophagitis in children and adults: A systematic review and consensus recommendations for diagnosis and treatment. Gastroenterology 2007, 133(4):1342-1363.
106. Ferguson DD, Foxx-Orenstein AE Eosinophilic esophagitis: An update. Dis Esophagus 2007, 20:2-8.
107. Faubion WA, Perrault J, Burgart LJ, et al. Treatment of eosinophilic esophagitis with inhaled corticosteroids. J Pediatr Gastroenterol Nutr 1998, 27:90-93.
108. Noel RJ, Putnam PE, Collins MH, et al. Clinical and immunopathologic effects of swallowed fluticasone for eosinophilic esophagitis. Clin Gastroenterol Hepatol 2004, 2:568-575.
109. Lehman MB, Clark SB, Ormsby AH, et al. Squamous mucosal alterations in esophagectomy specimens from patients with end-stage achalasia. Am J Surg Pathol 2001, 25:1413-1418.
110. Spechler SJ, Castell DO Classification of esophageal motility abnormalities. Gut 2001, 49:145-151.
111. Brais B, Xie YG, Sanson M, et al. The oculopharyngeal muscular dystrophy locus maps to the region of the cardiac alpha and beta myosin heavy chain genes on chromosome 14q11.2-q13. Hum Mol Genet 1995, 4:429-434.
112. Younes Z, Johnson DA The spectrum of spontaneous and iatrogenic esophageal injury: Perforations, Mallory-Weiss tears, and hematomas. J Clin Gastroenterol 1999, 29:306-317.
113. Tobin RW Esophageal rings, webs, and diverticula. J Clin Gastroenterol 1998, 27:285-295.
114. Schatzki R, Gary JE Dysphagia due to diaphragm-like narrowing in the lower esophagus ("lower esophageal ring"). Am J Roentgenol Radium Ther Nucl Med 1956, 75:246-261.
115. Atmatzidis K, Papaziogas B, Pavlidis T, et al. Plummer-Vinson syndrome. Dis Esophagus 2003, 16:154-157.
116. Rice TW Esophageal diverticula: Introduction. Semin Thorac Cardiovasc Surg 1999, 11(4):325.
117. Aly A, Devitt PG, Jamieson GG Evolution of surgical treatment for pharyngeal pouch. Br J Surg 2004, 91:657-664.
118. Reznik SI, Rice TW, Murthy SC, et al. Assessment of a pathophysiology-directed treatment for symptomatic epiphrenic diverticulum. Dis Esophagus 2007, 20:320-327.
119. Bhattacharya S, Mahmud S, McGlinchey I, et al. Intramural pseudodiverticulosis of the esophagus. Surg Endosc 2002, 16:714-715.
120. Mendez-Sanchez N, Chavez-Tapia NC, Vazquez-Elizondo G, Uribe M Eosinophilic gastroenteritis: A review. Dig Dis Sci Apr 2007, 11. [Epub ahead of print].
121. Rose S, Young MA, Reynolds JC Gastrointestinal manifestations of scleroderma. Gastroenterol Clin North Am 1998, 27:563-594.
122. Chua S, Dodd H, Saeed IT, et al. Dysphagia in a patient with lupus and review of the literature. Lupus 2002, 11:322-324.
123. Lopez-Cepero Andrada JM, Jimenez Arjona J, Amaya Vidal A, et al. Pseudoachalasia and secondary amyloidosis in a patient with rheumatoid arthritis. Gastroenterol Hepatol 2002, 25:398-400.
124. de Merieux P, Verity MA, Clements PJ, et al. Esophageal abnormalities and dysphagia in polymyositis and dermatomyositis. Arthritis Rheum 1983, 26:961-968.
125. Palma R, Freire A, Freitas J, et al. Esophageal motility disorders in patients with Sjögren's syndrome. Dig Dis Sci 1994, 39:758-761.
126. Fitzgerald RC, Triadafilopoulos G Esophageal manifestations of rheumatic disorders. Semin Arthritis Rheum 1997, 26:641-666.
127. Recht MP, Levine MS, Katzka DA, et al. Barrett's esophagus in scleroderma: Increased prevalence and radiographic findings. Gastrointest Radiol 1988, 13:1-5.
128. Weston S, Thumshirn M, Wiste J, Camilleri M Clinical and upper gastrointestinal motility features in systemic sclerosis and related disorders. Am J Gastroenterol 1998, 93:1085-1089.
129. Cozzi F, Zucchetta P, Durigon N, et al. Changes in esophageal peristalsis in diverse clinical forms and antibody specificity in scleroderma: A scintigraphic study in 100 cases. Reumatismo 2003, 55:86-92.
130. Lamireau T, Leaute-Labreze C, Le Bail B, et al. Esophageal involvement in Stevens-Johnson syndrome. Endoscopy 2001, 33:550-553.
131. Wise JL, Murray JA Esophageal manifestations of dermatologic disease. Curr Gastroenterol Rep 2002, 4:205-212.
132. Stewart MI, Woodley DT, Briggaman RA Epidermolysis bullosa acquisita and associated symptomatic esophageal webs. Arch Dermatol 1991, 127:373-377.
133. Abraham SC, Ravich WJ, Anhalt GJ, et al. Esophageal lichen planus: Case report and review of the literature. Am J Surg Pathol 2000, 24:1678-1682.
134. Gomi H, Akiyama M, Yakabi K, et al. Oesophageal involvement in pemphigus vulgaris. Lancet 1999, 354:1794.
135. Torzecka JD, Sysa-Jedrzejowska A, Waszczykowska E, et al. Immunopathological examination of esophagus as a useful criterion of cure in pemphigus vulgaris. J Eur Acad Dermatol Venereol 1999, 12:115-118.
136. Bernard P, Souyri N, Pillegand B, et al. Immunofluorescent studies of gastrointestinal tract mucosa in bullous pemphigoid. Arch Dermatol 1986, 122:137-138.
137. Shields MH, Shaffer K, O'Farrell RP, et al. Gastrointestinal manifestations of dermatologic disorders. Clin Gastroenterol Hepatol 2007, 5:1010-1017.
138. Johnston GA, Graham-Brown RAC The skin and disorders of the alimentary and the hepatobiliary system. Fitzpatrick's Dermatology in General Medicine 2003, 1609-98378. McGraw-Hill, New York. ed 6. T.B. Fitzpatrick, I.M. Freedberg (Eds.).
139. Jorizzo JL, Sherertz EF, Bennett ML Skin lesions associated with gastrointestinal disease. Textbook of Gastroenterology 1999, 992-98993. Lippincott Williams and Wilkins, Philadelphia. ed 3. T. Yamada, D.H. Alpers (Eds.).
140. Sodhi SS, Srinivasan R, Thomas RM Esophageal graft versus host disease. Gastrointest Endosc 2000, 52:235.
141. Otero Lopez-Cubero S, Sale GE, McDonald GB Acute graft-versus-host disease of the esophagus. Endoscopy 1997, 29:S35-36.
142. Minocha A, Mandanas RA, Kida M, et al. Bullous esophagitis due to chronic graft-versus-host disease. Am J Gastroenterol 1997, 92:529-530.
143. Nakshabendi IM, Maldonado ME, Coppola D, et al. Esophageal cast: A manifestation of graft-versus-host disease. Dig Dis 2000, 18:103-105.
144. Shulman HM, Kleiner D, Lee SJ, et al. Histopathologic diagnosis of chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: II. Pathology Working Group Report. Biol Blood Marrow Transplant 2006, 12(1):31-47.
145. Novak JM, Collins JT, Donowitz M, et al. Effects of radiation on the human gastrointestinal tract. J Clin Gastroenterol 1979, 1:9-39.
146. Trowers E, Thomas C, Silverstein FE Chemical- and radiation-induced esophageal injury. Gastrointest Endosc Clin N Am 1994, 4:657-675.
147. Decker GA, Loftus EV, Pasha TM, et al. Crohn's disease of the esophagus: Clinical features and outcomes. Inflamm Bowel Dis 2001, 7:113-119.
148. Tada S, Iida M, Iwashita A, et al. Endoscopic and biopsy findings of the upper digestive tract in patients with amyloidosis. Gastrointest Endosc 1990, 36:10-14.
149. Haggitt RC Barrett's esophagus, dysplasia and adenocarcinoma. Hum Pathol 1994, 25:982-993.
150. Hassal E Barrett's esophagus: New definitions and approaches in children. J Pediatr Gastroenterol Nut 1993, 16:345-364.
151. Wild CP, Hardie LJ Reflux, Barrett's oesophagus and adenocarcinoma: Burning questions. Nat Rev 2003, 3:676-685.
152. Spechler SJ Barrett's esophagus and esophageal adenocarcinoma: Pathogenesis, diagnosis, and therapy. Med Clin North Am 2002, 86(6):1423-1445.
153. Sharma P, McQuaid K, Dent J, et al. A critical review of the diagnosis and management of Barrett's esophagus: The AGA Chicago Workshop. Gastroenterology 2004, 127(1):310-330.
154. Odze R Diagnosis and grading of dysplasia in Barrett's oesophagus. J Clin Pathol 2006, 59:1029-1038.
155. Sampliner RE Updated guidelines for the diagnosis, surveillance and therapy of Barrett's esophagus. Am J Gastroenterol 2002, 97(8):1888-1895.
156. Riddell RH The biopsy diagnosis of gastroesophageal reflux disease, "carditis," and Barrett's esophagus, and sequelae of therapy. Am J Surg Pathol 1996, 20(Suppl 1):S31-50.
157. Odze R Unraveling the mystery of the gastroesophageal junction. Am J Gastroenterol 2005, 100:1853-1867.
158. Iftikhar SY, James PD, Steele RJ, et al. Length of Barrett's oesophagus: An important factor in the development of dysplasia and adenocarcinoma. Gut 1992, 33(9):1155-1158.
159. Menke-Pluymers MB, Hop WC, Dees J, et al. Risk factor for the development of an adenocarcinoma in columnar-lined (Barrett) esophagus. The Rotterdam Esophageal Tumor Study Group. Cancer 1993, 72(4):1155-1158.
160. Weston AP, Sharma P, Mathur S, et al. Risk stratification of Barrett's esophagus: Updated prospective multivariate analysis. Am J Gastroenterol 2004, 99(9):1657-1666.
161. Sharma P, Dent J, Armstrong D, et al. The development and validation of an endoscopic grading system for Barrett's esophagus: The Prague C and M criteria. Gastroenterology 2006, 131(5):1392-1399.
162. Hahn H, Blount P, Ayub K, et al. Non-goblet (cardia-type) epithelium in Barrett's esophagus is "intestinalized": Implications with regard to the pathogenesis of this disorder. Mod Pathol 2007, 20(Suppl 2):11A.
163. Glickman JN, Wang H, Das KM, et al. Phenotype of Barrett's esophagus and intestinal metaplasia of the distal esophagus and gastroesophageal junction: An immunohistochemical study of cytokeratins 7 and 20, Das-1 and 45 MI. Am J Surg Pathol 2001, 25(1):87-94.
164. Srivastava A, Hornick JL, Li X, et al. Loss of goblet cell differentiation occurs with the progression of dysplasia in Barrett's esophagus. Gastroenterology 2006, 130(Suppl 2):A-264.
165. Sharma P, McElhinney C, Topalovski M, et al. Detection of cardia intestinal metaplasia: Do the biopsy number and location matter?. Am J Gastroenterol 2004, 99:2424-2428.
166. Oberg S, Johansson J, Wenner J, et al. Endoscopic surveillance of columnar-lined esophagus: Frequency of intestinal metaplasia detection and impact of antireflux surgery. Ann Surg 2001, 234(5):619-626.
167. Harrison R, Perry I, Haddadin W, et al. Detection of intestinal metaplasia in Barrett's esophagus: An observational comparator study suggests the need for a minimum of eight biopsies. Am J Gastroenterol 2007, 102(6):1154-1161.
168. Spechler SJ Intestinal metaplasia at the gastroesophageal junction. Gastroenterology 2004, 126:567-575.
169. Ofman JJ, Shaheen NJ, Desai AA, et al. The quality of care in Barrett's esophagus: Endoscopist and pathologist practices. Am J Gastroenterol 2001, 96:876-881.
170. Sharma P Review article: Prevalence of Barrett's oesophagus and metaplasia at the gastrooesophageal junction. Aliment Pharmacol Ther 2004, 20(Suppl 5):48-54.
171. Ronkainen J, Aro P, Storskrubb T, et al. Prevalence of Barrett's esophagus in the general population: An endoscopic study. Gastroenterology 2005, 129(6):1825-1831.
172. Winters C, Spurling TJ, Chobanian SJ, et al. Barrett's esophagus. A prevalent, occult complication of gastroesophageal reflux disease. Gastroenterology 1987, 92(1):118-124.
173. Rex DK, Cummings OW, Shaw M, et al. Screening for Barrett's esophagus in colonoscopy patients with and without heartburn. Gastroenterology 2003, 125(6):1670-1677.
174. Conio M, Cameron AJ, Romero Y, et al. Secular trends in the epidemiology and outcome of Barrett's oesophagus in Olmsted County, Minnesota. Gut 2001, 48:304-309.
175. Conio M, Filiberti R, Blanchi S, et al. Risk factors for Barrett's esophagus: A case-control study. Int J Cancer 2002, 97:225-229.
176. Prach AT, MacDonald TA, Hopwood DA, Johnson DA Increasing incidence of Barrett's oesophagus: Education, enthusiasm, or epidemiology?. Lancet 1997, 350:933.
177. Souza RF, Spechler SJ Concepts in the prevention of adenocarcinoma of the distal esophagus and proximal stomach. CA Cancer J Clin 2005, 55(6):334-351.
178. Cameron AJ Epidemiology of columnar-lined esophagus and adenocarcinoma. Gastroenterol Clin North Am 1997, 26:487-494.
179. Grupo Operativo per lo Studio delle Precancerosi dell'Esofago (GOSPE) Barrett's esophagus: Epidemiological and clinical results of a multicentric survey. Int J Cancer 1991, 48:364-368.
180. MacInnis RJ, English DR, Hopper JL, Giles GG: Body size and composition and the risk of gastric and oesophageal adenocarcinoma, Int J Cancer 2006, 118:2628-2631.
181. Chow WH, Blot WJ, Vaughan TL, et al. Body mass index and risk of adenocarcinomas of the esophagus and gastric cardia. J Natl Cancer Inst 1998, 90:150-155.
182. Hampel H, Abraham NS, El-Serag HB Meta-analysis: Obesity and risk for gastroesophageal reflux disease and its complications. Ann Intern Med 2005, 143:199-211.
183. Jacobson BC, Somers SC, Fuchs CS, et al. Body-mass index and symptoms of gastroesophageal reflux in women. N Engl J Med 2006, 354:2340-2348.
184. Stein DJ, El-Serag HB, Kuczynski J, et al. The association of body mass index with Barrett's oesophagus. Aliment Pharmacol Ther 2005, 22:1005-1010.
185. Edelstein ZR, Farrow DC, Bronner MP, et al. Central adiposity and risk of Barrett's esophagus. Gastroenterology 2007, 133:403-411.
186. Hassall E, Weinstein WM, Ament ME Barrett's esophagus in childhood. Gastroenterology 1985, 89(6):1331-1337.
187. Qualman SJ, Murray RD, McClun J, et al. Intestinal metaplasia is age related in Barrett's esophagus. Arch Pathol Lab Med 1990, 114:1236-1240.
188. Hu Y, Jones C, Gellersen O, et al. Pathogenesis of Barrett's esophagus. Arch Surg 2007, 142:540-545.
189. Krishnadath KK Novel pathogenesis of esophageal columnar metaplasia or Barrett's esophagus. Curr Opin Gastroenterol 2007, 23:440-445.
190. Fitzgerald RC, Omary MB, Triadafilopoulos G Dynamic effects of acid on Barrett's esophagus: An ex vivo proliferation and differentiation model. J Clin Invest 1996, 98:2120-2128.
191. Glickman JN, Fox V, Antonioli DA, et al. Morphology of the cardia and significance of carditis in pediatric patients. Am J Surg Pathol 2002, 26(8):1032-1039.
192. DeMeester SR, Wickramasinghe KS, Lord RVN, et al. Cytokeratin and DAS-1 immunostaining reveal similarities among cardiac mucosa, CIM, and Barrett's esophagus. Am J Gastroenterol 2002, 97(10):2514-2523.
193. Oberg S, Demeester TR, Peter JH, et al. The extent of Barrett's esophagus depends on the status of the lower esophageal sphincter and the degree of esophageal acid exposure. J Thorac Cardiovasc Surg 1999, 117:572-580.
194. Vaezi MF, Richter JE Bile reflux in columnar-lined esophagus. Gastroenterol Clin North Am 1997, 26:565-582.
195. Houghton JM, Stoicov C, Nomura S, et al. Gastric cancer origination from bone marrow-derived cells. Science 2004, 306:1568-1571.
196. Thiery JP Epithelial-mesenchymal transitions in development and pathologies. Curr Opin Cell Biol 2003, 15:740-746.
197. Li H, Walsh TN, O'Dowd G, et al. Mechanisms of columnar metaplasia and squamous regeneration in experimental Barrett's esophagus. Surgery 1994, 115:176-181.
198. Gillen P, Keeling P, Byrne PJ, et al. Experimental columnar metaplasia in the canine oesophagus. Br J Surg 1988, 75:113-115.
199. Shields HM, Zwas FR, Antonioli DA, et al. Detection by scanning electron microscopy of a distinctive esophageal surface cell at the junction of squamous and Barrett's epithelium. Dig Dis Sci 1993, 39:97-108.
200. Shields H, Rosenberg SJ, Zwas FR, et al. Prospective evaluation of multilayered epithelium in Barrett's esophagus. Am J Gastroenterol 2001, 96(12):3268-3273.
201. Hornick JL, Blount PL, Sanchez CA, et al. Biologic properties of columnar epithelium underneath reepithelialized squamous mucosa in Barrett's esophagus. Am J Surg Pathol 2005, 29(3):372-380.
202. Gore S, Healy CJ, Sutton R, et al. Regression of columnar lined (Barrett's) oesophagus with continuous omeprazole therapy. Aliment Pharmacol Ther 1993, 7(6):623-628.
203. Mino-Kenudson M, Ban S, Ohana M, et al. Buried dysplasia and early adenocarcinoma arising in Barrett's esophagus after porfimer-photodynamic therapy. Am J Surg Pathol 2007, 31(3):403-409.
204. Thurberg B, Duray P, Odze R Polypoid dysplasia in Barrett's esophagus: A clinicopathologic, immunohistochemical and molecular study of five cases. Human Pathol 1999, 30(7):745-752.
205. Antonioli DA, Wang HH Morphology of Barrett's esophagus and Barrett's-associated dysplasia and adenocarcinoma. Gastroenterol Clin North Am 1997, 26:495-506.
206. Wang HH, Zeroogian JM, Spechler SJ, et al. Prevalence and significance of pancreatic acinar metaplasia at the gastroesophageal junction. Am J Surg Pathol 1996, 20:1507-1510.
207. Hornick JL, Odze RD Neoplastic precursor lesions in Barrett's esophagus. Gastroenterol Clin North Am 2007, 36:775-796.
208. Wong DJ, Paulson TG, Prevo LJ, et al. P16(INK4a) lesions are common, early abnormalities that undergo clonal expansion in Barrett's metaplastic epithelium. Cancer Res 2001, 61(22):8284-8289.
209. Campomenosi P, Conio M, Bogliolo M, et al. P53 is frequently mutated in Barrett's metaplasia of the intestinal type. Cancer Epidemiol Biomarkers Prev 1996, 5(7):559-565.
210. Souza RF, Morales CP, Spechler SJ A conceptual approach to understanding the molecular mechanisms of cancer development in Barrett's oesophagus. Aliment Pharmacol Ther 2001, 15:1087-1100.
211. Hahn H, Liu W, Goyal R, Odze RD DNA ploidy abnormalities in non-goblet and goblet columnar epithelium in Barrett's esophagus. Mod Pathol 2008, 21(S1):553A.
212. Hahn H, Shahsafei A, Odze RD Vascular and lymphatic properties of the superficial and deep lamina propria in Barrett's esophagus. Lab Invest 2007, 87(S1):130A.
213. Srivastava A, Odze RD, Lauwers G, et al. Morphological features are useful in distinguishing Barrett's esophagus from carditis with intestinal metaplasia. Am J Surg Pathol 2007, 31(11):1733-1741.
214. Haggitt RC, Reid BJ, Rubin CE, et al. Barrett's esophagus: Correlation between mucin histochemistry, flow cytometry and histologic diagnosis for predicting increased cancer risk. Am J Pathol 1988, 131:53-61.
215. Chen YY, Wang H, Antonioli D, et al. Significance of acid-mucin-positive non-goblet columnar cells in the distal esophagus and gastro-esophageal junction. Human Pathol 1999, 30(12):1488-1495.
216. Lauwers GY, Scott GV, Vauthey GN Adenocarcinoma of the upper esophagus arising in cervical ectopic gastric mucosa: Rare evidence of malignant potential of so-called "inlet patch.". Dig Dis Sci 1998, 43:901-907.
217. Johansson J, Hakansson HO, Mellblom L, et al. Prevalence of precancerous and other metaplasia in the distal oesophagus and gastro-oesophageal junction. Scand J Gastroenterol 2005, 40:893-902.
218. Weinstein WM, Ippoliti AF The diagnosis of Barrett's esophagus: Goblets, goblets, goblets. Gastrointest Endosc 1996, 44:91-95.
219. Reid BJ, Haggitt RC, Rubin CE, et al. Observer variation in the diagnosis of dysplasia in Barrett's esophagus. Hum Pathol 1988, 19(2):166-178.
220. Schlemper RJ, Riddell RH, Kato Y, et al. The Vienna classification of gastrointestinal epithelial neoplasia. Gut 2000, 47(2):251-255.
221. Mayne ST, Risch HA, Dubrow R, et al. Nutrient intake and risk of subtypes of esophageal and gastric cancer. Cancer Epidemiol Biomarkers Prev 2001, 10:1055-1062.
222. Zhang ZF, Kurtz RC, Yu GP, et al. Adenocarcinomas of the esophagus and gastric cardia: The role of diet. Nutr Cancer 1997, 27:298-309.
223. Lagergren J, Bergstrom R, Lindgren A, Nyren O The role of tobacco, snuff and alcohol use in the aetiology of cancer of the oesophagus and gastric cardia. Int J Cancer 2000, 85:340-346.
224. McManus DT, Olaru A, Meltzer SJ Biomarkers of esophageal adenocarcinoma and Barrett's esophagus. Cancer Res 2004, 64(5):1561-1569.
225. Galipeau PC, Cowan DS, Sanchez CA, et al. 17p (p53) allelic losses, 4N (G2/tetraploid) populations, and progression to aneuploidy in Barrett's esophagus. Proc Natl Acad Sci U S A 1996, 93(14):7081-7084.
226. Reid BJ P53 and neoplastic progression in Barrett's esophagus. Am J Gastroenterol 2001, 96(5):1321-1323.
227. Hong MK, Laskin WB, Herman BE, et al. Expansion of the Ki-67 proliferative compartment correlates with degree of dysplasia in Barrett's esophagus. Cancer 1995, 75(2):423-429.
228. Reid BJ, Prevo IJ, Galipeau PC, et al. Predictors of progression in Barrett's esophagus II: Baseline 17p (p53) loss of heterozygosity identifies a patient subset at increased risk for neoplastic progression. Am J Gastroenterol 2001, 96(10):2839-2848.
229. Rabinovitch PS, Longton G, Blount PL, et al. Predictors of progression in Barrett's esophagus III: Baseline flow cytometric variables. Am J Gastroenterol 2001, 96(11):3071-3083.
230. Reid BJ, Levine DS, Longton G, et al. Predictors of progression to cancer in Barrett's esophagus: Baseline histology and flow cytometry identify low- and high-risk patient subsets. Am J Gastroenterol 2000, 95(7):1669-1676.
231. Buttar NS, Wang KK, Sebo TJ, et al. Extent of high-grade dysplasia in Barrett's esophagus correlates with risk of adenocarcinoma. Gastroenterology 2001, 120(7):1630-1639.
232. Montgomery E, Bronner MP, Greenson JK, et al. Are ulcers a marker for invasive carcinoma in Barrett's esophagus? Data from a diagnostic variability study with clinical follow-up. Am J Gastroenterol 2002, 97(1):27-31.
233. Montgomery E, Bronner MP, Goldblum JR, et al. Reproducibility of the diagnosis of dysplasia in Barrett esophagus: A reaffirmation. Hum Pathol 2001, 32(4):368-378.
234. Lomo LC, Blount PL, Sanchez CA, et al. Crypt dysplasia with surface maturation: A clinical, pathologic, and molecular study of a Barrett's esophagus cohort. Am J Surg Pathol 2006, 30(4):423-435.
235. Zhang X, Goyal R, Huang Q, Odze RD DNA ploidy abnormalities in basal and superficial regions of the crypts in Barrett's esophagus and associated neoplastic lesions. Am J Surg Pathol 2008, (in press).
236. Rucker-Schmidt RL, Sanchez CA, Blount PL, et al. Non-adenomatous dysplasia in Barrett's esophagus: A clinical, pathologic and molecular study. Mod Pathol 2008, 21(S1):527A.
237. Srivastava A, Hornick JL, Li X, et al. Loss of goblet cell differentiation occurs with the progression of dysplasia in Barrett's esophagus. Gastroenterology 2006, 130(S2):A-264.
238. Abraham S, Krasinskas A, Correa A, et al. Duplication of the muscularis mucosae in Barrett esophagus: An underrecognized feature and its implication for staging of adenocarcinoma. Am J Surg Pathol 2007, 31(11):1719-1725.
239. Ornsby AH, Petras RE, Henricks WH, et al. Observer variation in the diagnosis of superficial oesophageal adenocarcinoma. Gut 2002, 51(5):671-676.
240. Mino-Kenudson M, Hull MJ, Brown I, et al. Endoscopic mucosal resection for Barrett's esophagus-related superficial neoplasms offers better diagnostic reproducibility than mucosal biopsy. Gastrointest Endosc 2007, 66(4):660-666.
241. Levine DS, Haggitt RC, Blount PL, et al. A systematic endoscopic biopsy protocol can differentiate high-grade dysplasia from early adenocarcinoma in Barrett's esophagus. Gastroenterology 1993, 105:40-50.
242. Reid BJ, Blount PL, Feng Z, Levine DS Optimizing endoscopic biopsy detection of early cancers in Barrett's high-grade dysplasia. Am J Gastroenterol 2000, 95:3089-3096.
243. Kerkhof M, Van Dekken H, Steyerberg EW, et al. Grading of dysplasia in Barrett's oesophagus: Substantial interobserver variation between general and gastrointestinal pathologists. Histopathology 2007, 50(7):920-927.
244. Srivastava A, Hornick JL, Li X, et al. Extent of low-grade dysplasia is a risk factor for the development of esophageal adenocarcinoma in Barrett's esophagus. Am J Gastroenterol 2007, 102(3):483-493.
245. Skacel M, Petras RE, Gramlich TL, et al. The diagnosis of low-grade dysplasia in Barrett's esophagus and its implications for disease progression. Am J Gastroenterol 2000, 95(12):3383-3387.
246. Montgomery E, Goldblum JR, Greenson JK, et al. Dysplasia as a predictive marker for invasive carcinoma in Barrett's esophagus: A follow-up study based on the 138 cases from a diagnostic variability study. Hum Pathol 2001, 32(4):379-388.
247. Wilkinson SP, Biddlestone L, Gore S, Shepherd NA Regression of columnar-lined (Barrett's) oesophagus with omeprazole 40° mg daily: Results of 5 years of continuous therapy. Aliment Pharmacol Ther 1999, 13:1205-1209.
248. Hage M, Siersema PD, Van Dekken H, et al. 5-aminolevulinic acid photodynamic therapy versus argon plasma coagulation for ablation of Barrett's oesophagus: A randomized trial. Gut 2004, 53(6):785-790.
249. Sharma P, Morales TG, Bhattacharyya A, et al. Squamous islands in Barrett's esophagus: What lies beneath?. Am J Gastroenterol 1998, 93:332-335.
250. Biddlestone LR, Barham CP, Wilkinson SP, et al. The histopathology of treated Barrett's esophagus. Am J Surg Pathol 1998, 22:239-245.
251. Overholt BF, Wang KK, Burdick JS, on behalf of the International Photodynamic Group for High-Grade Dysplasia in Barrett's Esophagus, et al. Five-year efficacy and safety of photodynamic therapy with Photofrin in Barrett's high-grade dysplasia. Gastrointest Endosc 2007, 66:460-468.
252. Younes M, Lebovitz RM, Lechago LV, et al. P53 protein accumulation in Barrett's metaplasia, dysplasia, and carcinoma: A follow-up study. Gastroenterology 1993, 105(6):1637-1642.
253. Dorer R, Odze RD AMACR immunostaining is useful in detecting dysplastic epithelium in Barrett's esophagus, ulcerative colitis, and Crohn's disease. Am J Surg Pathol 2006, 30(7):871-877.
254. Lisovsky M, Falkowski O, Bhuiya T Expression of alpha-methylacyl-coenzyme A racemase in dysplastic Barrett's epithelium. Hum Pathol 2006, 37(12):1601-1606.
255. Weston AP, Banerjee SK, Sharma P, et al. P53 protein overexpression in low grade dysplasia (LGD) in Barrett's esophagus: Immunohistochemical marker predictive of progression. Am J Gastroenterol 2001, 96(5):1355-1362.
256. Dar MS, Goldblum JF, Rice TW, et al. Can extent of high grade dysplasia in Barrett's oesophagus predict the presence of adenocarcinoma at oesophagectomy?. Gut 2003, 52(4):486-489.
257. Srivastava A, Hornick JL, Li X, et al. Extent of low-grade dysplasia is a risk factor for the development of esophageal adenocarcinoma in Barrett's esophagus. Am J Gastroenterol 2007, 102(3):483-493.
258. Schnell TG, Sontag SJ, Chejfec G, et al. Long-term nonsurgical management of Barrett's esophagus with high-grade dysplasia. Gastroenterology 2001, 120:1607-1619.
259. Miros M, Kerlin P, Walker N Only patients with dysplasia progress to adenocarcinoma in Barrett's oesophagus. Gut 1991, 32(12):1441-1446.
260. Robertson CS, Mayberry JF, Nicholson DA, et al. Value of endoscopic surveillance in the detection of neoplastic change in Barrett's oesophagus. Br J Surg 1988, 75(8):760-763.
261. O'Connor JB, Falk GW, Richter JE The incidence of adenocarcinoma and dysplasia in Barrett's esophagus: Report on the Cleveland Clinic Barrett's Esophagus Registry. Am J Gastroenterol 1999, 94(8):2037-2042.
262. Overholt BF, Lightdale CJ, Wang KK, et al. International Photodynamic Group for High-Grade Dysplasia in Barrett's Esophagus. Photodynamic therapy with porfimer sodium for ablation of high-grade dysplasia in Barrett's esophagus: International, partially blinded, randomized phase III trial. Gastrointest Endosc 2005, 62:488-498.
263. Gastrointest Endosc 2006, 63:359. Erratum.
264. Sharma P, Wani S, Weston AP, et al. A randomized controlled trial of ablation of Barrett's oesophagus with multipolar electrocoagulation versus argon plasma coagulation in combination with acid suppression: Long term results. Gut 2006, 55:1233-1239.
265. Franchimont D, Van Laethem JL, Deviere J Argon plasma coagulation in Barrett's esophagus. Gastrointest Endosc Clin N Am 2003, 13:457-466.
266. Lightdale CJ Ablation therapy for Barrett's esophagus: Is it time to choose our weapons?. Gastrointest Endosc 1999, 49:122-125.
267. Johnston MH Cryotherapy and other newer techniques. Gastrointest Endosc Clin N Am 2003, 13:491-504.
268. Weston AP Use of lasers in Barrett's esophagus. Gastrointest Endosc Clin N Am 2003, 13:467-481.
269. Prasad GA, Wang KK, Buttar NS, et al. Long-term survival following endoscopic and surgical treatment of high-grade dysplasia in Barrett's esophagus. Gastroenterology 2007, 132:1226-1233.
270. Veith M, Ell C, Gossner L, et al. Histological analysis of endoscopic resection specimens from 326 patients with Barrett's esophagus and early neoplasia. Endoscopy 2004, 36:776-781.
271. Wolfsen HC Endoluminal therapy for Barrett's esophagus. Gastrointest Endosc Clin N Am 2007, 17:59-82.
272. Gluch L, Smith RC, Bambach CP, Brown AR Comparison of outcomes following transhiatal or Ivor Lewis esophagectomy for esophageal carcinoma. World J Surg 1999, 23(3):271-275. discussion 275-276.
273. Goldminc M, Maddern G, Le Prise E, et al. Oesophagectomy by a transhiatal approach or thoracotomy: A prospective randomized trial. Br J Surg 1993, 80(3):367-370.